Briefly, T-DM1 presented a lower PFS, ORR, and tendency to lower OS than T-DXd, which dominated all the schemes studied in patients with advanced or locoregionally advanced HER2+ BC in patients previously progressed to trastuzumab and taxanes. The gene discussed is ERBB2; the disease is breast cancer.